SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto

Patent metadata

Field	Value
Publication number	US-9931374-B2
Application number	US-201514753665-A
Country	US
Kind code	B2
Filing date	Jun 29, 2015
Priority date	Jun 10, 2009
Publication date	Apr 3, 2018
Grant date	Apr 3, 2018

Abstract

The present invention relates to Sor CS1-like agents, including Sor CS1, nucleic acid molecule encoding expression of Sor CS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing Sor CS1 and said fragments, for use in the treatment of insulin resistance.

First claim

The invention claimed is:

1. A method of treatment of insulin resistances and/or a disease associated with insulin resistance selected from the group consisting of insulin resistance syndrome, Type 2 diabetes mellitus, impaired glucose tolerance, and any combination thereof, said method comprising administering to an individual in need thereof a therapeutically effective amount of a composition comprising a vector comprising a nucleic acid sequence encoding a polypeptide selected from the group consisting of:
(i) an amino acid sequence consisting of SEQ ID NO: 15;
(ii) a biologically active homolog of the amino acid sequence of (i)
wherein said homolog has at least 90% sequence identity to said SEQ ID NO: 15, and
wherein said homolog competes for binding with the polypeptide of (i) to a SorCS1 binding site of an insulin receptor; and

(iii) a biologically active fragment of the amino acid sequence of SEQ ID NO: 15 wherein said fragment consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94 and SEQ ID NO: 95, and wherein said fragment competes for binding with the polypeptide of (i) to a SorCS1 binding site of an insulin receptor.

2. The method according to claim 1 , wherein said polypeptide consists of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 5, 10, 15, 21, 27, 33, 37, 39, 43 and 47.

3. The method according to claim 1 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 5.

4. The method according to claim 1 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 10.

5. The method according to claim 1 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 15.

6. The method according to claim 1 , wherein said polypeptide has at least 98% sequence identity to SEQ ID NO: 15.

7. The method according to claim 1 , wherein said polypeptide has at least 99% sequence identity to SEQ ID NO: 15.

8. The method according to claim 1 , wherein the disease associated with insulin resistance is insulin resistance syndrome.

9. The method according to claim 1 , wherein the disease associated with insulin resistance is Type 2 diabetes mellitus.

10. The method according to claim 1 , wherein the disease associated with insulin resistance is impaired glucose tolerance.

Assignees

• Univ Aarhus

Inventors

• Pedersen Karen-Marie
• Nykjaer Anders

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title